Search results

Technologies 36

View all

• GC Therapeutics: Changing the Future of Cell Therapies
  GC Therapeutics (GCTx) is applying their stem cell-engineering TFome platform to overcome barriers in the development and manufacturing of cell therapies to improve patient access across a broad range of disease areas.
• Instrument-Free Molecular Diagnostics
  A synthetic biology-based molecular diagnostics platform that enables the creation of low-cost, highly accurate tests for non-clinical settings.
• AminoX: Making Better Protein Drugs, Quicker and Cheaper
  AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition.
• Engineered Live Biotherapeutic Product (eLBP) to Protect the Microbiome from Antibiotics
  eLBP is a safe and cost-effective therapeutic for patients treated with beta-lactam antibiotics that safeguards against the loss of health-essential microbes while preventing the development and spread of antibiotic resistance.
• Ichor: Reversing Aging
  Ichor is addressing multiple age-related diseases by identifying genetic interventions that reprogram old cells to a younger state. Therapies based on these interventions could improve survival for cancer patients and long-term cardiovascular and neurological health.
• Crisscross Nanoseed Detection: Nanotechnology-Powered Infectious Disease Diagnostics
  This nanotech-based diagnostic platform uses a unique nucleation mechanism that assembles a DNA "nanoseed" in the presence of a pathogen-derived biomarker that then is amplified within 15 minutes to create a signal for easy detection. It is highly robust, and cost-effective, and can be adapted to detect a variety of biomarkers.

Collaborations 1

• Brigham-Wyss DxA
  The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests.

News 258

View all

• Press Release
  
  Toward recreating the brain’s immune system in a dish
  June 10, 2025
• Community
  
  Elizabeth Hann on Using Microbes to Save the Earth
  April 29, 2025
• Press Release
  
  Wyss Institute at Harvard University launches its Diagnostics for Human and Planetary Health platform headed by David Walt
  February 10, 2025

Multimedia 76

View all

• 

  Video/Animation
  George Church: Embracing Outliers in Science and in Life
  George Church, Ph.D., is a Core Faculty member at the Wyss Institute and a genetics professor at Harvard Medical School. He is a pioneer in synthetic biology and personalized genomics. In 2017, Time magazine named him as one of the 100 most influential people in the world. In addition to being a scientist, Church is...

• 

  Video/Animation
  20-ish Questions with Pamela Silver
  20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows Pamela Silver, a Founding Core Faculty member of the Wyss Institute as well as the Elliot T. and Onie H. Adams Professor of Biochemistry and Systems Biology at...

• 

  Video/Animation
  The End of Aging—And Extinction | George Church, Ph.D. on Longevity, Dire Wolves, and Woolly Mammoths
  What if aging was optional—and extinction reversible? In this episode of Ignition Sequence, Wyss Core Faculty member and geneticist and biotech pioneer, George Church, Ph.D., joins host Dylan Bohbot to explore the frontiers of gene therapy, de-extinction, and the future of human health. A founding scientist behind the Human Genome Project, and co-founder of Colossal...

• 

  Video/Animation
  Finding a Balance In Bipolar Disorder Through Drug Prediction and Organoid-Based Drug Screening
  CircaVent is a high-throughput drug screening platform that combines predictive algorithms, preclinical models, and human brain organoids to efficiently identify and test drugs that could treat the underlying causes of bipolar disorder. CircaVent is initially focused on addressing the circadian rhythm disruptions that are a common hallmark of BD, and could dramatically speed up the...

• 

  Video/Animation
  Human Skin Rejuvenation: Li Li, Ph.D.
  In this episode of Conquer Aging or Die Trying, host Michael Lustgarten, Ph.D. speaks to Wyss Postdoctoral Fellow Li Li, Ph.D. about the technology she’s developing for skin rejuvenation.  

• 

  Video/Animation
  20-ish Questions with George Church
  20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows George Church, a founding Core Faculty member of the Wyss Institute and lead of the Synthetic Biology Focus Area. Credit: Wyss Institute at Harvard University